trending Market Intelligence /marketintelligence/en/news-insights/trending/cjQf11uhZ33I0qcbfxG3lw2 content esgSubNav
In This List

Helix BioPharma raises C$7M via private placement for cancer R&D activities

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Helix BioPharma raises C$7M via private placement for cancer R&D activities

Helix BioPharma Corp. raised about C$7 million in gross proceeds via a private placement of units and by the disposition of a 25% stake its Polish subsidiary, Helix Immuno Oncology SA.

The Ontario-based company issued 13,725,000 units under the placement. Each unit is priced at 45.5 Canadian cents apiece and comprises 1common share and a share purchase warrant. A warrant will enable the holder to buy a common share at an exercise price of 72 Canadian cents and will expire within five years of issuance.

The terms of the placement include the sale of the Polish subsidiary shares.

Helix BioPharma, which develops products for preventing and treating cancer, plans to use the net placement proceeds for working capital and research and development activities.

Jerzy Wilczewski, the investor who acquired all the units in the placement, said his family wanted to contribute to cancer research development. "I decided to make this sizable investment in Helix because I believe in the social objective and the uniqueness of the company's technology. An additional motivation for me is the ongoing research and development work that the company is carrying on in Poland."

ACM Alpha Consulting Management AG acted as the financial adviser to the company with the private placement.